Stay updated on TAK-861 Study in Narcolepsy Type 2 Clinical Trial
Sign up to get notified when there's something new on the TAK-861 Study in Narcolepsy Type 2 Clinical Trial page.

Latest updates to the TAK-861 Study in Narcolepsy Type 2 Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check41 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check49 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check63 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check70 days agoChange DetectedThe latest updates include the posting of results for the TAK-861 study, detailing interventions with 2 mg and 5 mg dosages, and new metrics for evaluating sleep latency and daytime sleepiness, while previous entries related to earlier dosing and assessments have been removed.SummaryDifference21%
- Check92 days agoChange DetectedResults have been submitted, replacing the previous status of no results posted.SummaryDifference0.1%
Stay in the know with updates to TAK-861 Study in Narcolepsy Type 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAK-861 Study in Narcolepsy Type 2 Clinical Trial page.